Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 6Mouth Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Carcinoma 4Oropharyngeal Neoplasms 3Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Capecitabine 24Oxaliplatin 21Fluorouracil 16Radiotherapy 12Leucovorin 10Cetuximab 9Nivolumab 7Bevacizumab 6sintilimab 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Irinotecan 5Folfox protocol 5trifluridine tipiracil drug combination 4pembrolizumab 4Surgical Procedures, Operative 4encorafenib 3X-Rays 3Trastuzumab 3Surveys and Questionnaires 3Sigmoidoscopy 3Radiation 3Pemetrexed 3Gemcitabine 3Endoscopy 3Control Groups 3Consolidation Chemotherapy 3Cisplatin 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × (225)Ac-DOTA-c(RGDyK) × 90 days × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡